Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Molecular targeted agents represent significant advances in clinical oncology.
• These agents are commonly combined with chemotherapy for breast, colon, and lung cancers.
• Despite progress, targeted therapy development encounters limitations and past study failures.

Purpose of the Study:

• To discuss the limitations encountered in molecular targeted agent development.
• To analyze failures from previous targeted therapy studies.
• To propose strategies for more intelligent drug development in oncology.

Main Methods:

• Review of existing literature on molecular targeted agents in oncology.
• Analysis of specific case studies including mTOR inhibitors in breast cancer.
• Examination of anti-EGFR therapy efficacy in lung and colon cancer, considering KRAS mutation status.

Main Results:

• Initial mTOR blockade attempts in breast cancer showed limited benefit.
• Anti-EGFR therapy demonstrated significant benefit in lung cancer.
• Colon cancer treatment with anti-EGFR therapy is increasingly guided by KRAS mutation status.

Conclusions:

• Targeted therapy development requires overcoming significant limitations and past failures.
• Intelligent drug development strategies are necessary for optimizing cancer treatment.
• Personalized approaches, like KRAS-based selection for anti-EGFR therapy, are vital.